Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Total Non-Current Liabilities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $70.3 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 51.72% to $70.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.3 million through Dec 2025, down 51.72% year-over-year, with the annual reading at $70.3 million for FY2025, 51.72% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $70.3 million at Lexicon Pharmaceuticals, down from $78.2 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $169.3 million in Q1 2025, with the low at $69.2 million in Q1 2023.
  • Average Total Non-Current Liabilities over 3 years is $114.3 million, with a median of $126.1 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities rose 11.06% in 2024, then plummeted 51.72% in 2025.
  • Over 3 years, Total Non-Current Liabilities stood at $131.1 million in 2023, then grew by 11.06% to $145.5 million in 2024, then tumbled by 51.72% to $70.3 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $70.3 million, $78.2 million, and $90.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.